Form 4: Solid Biosciences Director Adam Stone Acquires Stock Options

Solid Biosciences director Adam Stone was granted 34,400 stock options on June 11, 2024, which vest within one year or upon a change of control.

Summary

• Adam Stone, a director at Solid Biosciences, was granted 34,400 stock options on June 11, 2024.
• The options have an exercise price of $7.51 per share.
• These options vest in full on the earlier of one year from the grant date or immediately before the next annual meeting of stockholders.
• The options will also vest automatically upon a change in control of the company.
• The options expire on June 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The granting of stock options to a director aligns their interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard practice for incentivizing board members in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotech industry, similar to companies like BioMarin Pharmaceutical and Sarepta Therapeutics.
• The vesting schedule of one year or upon a change of control is also typical, aligning with industry norms for incentivizing long-term performance and retention.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to better decision-making.
• The vesting schedule encourages long-term commitment from the director, which can benefit the company and its stakeholders.

Key Dates

Keywords

stock options, director, insider trading, equity, Solid Biosciences, SLDB, vesting